Nebulgen Adulti (Flunisolide)

Flunisolide, the active ingredient in Nebulgen Adulti, is a glucocorticoid presented as an inhalation formulation for inhalation use. It is indicated for the treatment of asthma in adult patients, helping to reduce airway inflammation and improve breathing control.

GNH USA supplies Nebulgen Adulti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides reliable global distribution.

Flunisolide is an inhaled glucocorticoid that targets airway inflammation in respiratory disorders. - Asthma: reduces airway inflammation, improves symptom control, and decreases frequency of exacerbations. - Allergic airway inflammation: diminishes inflammatory response to allergens, helping maintain lung function. - Bronchial hyperreactivity: lessens airway hyperresponsiveness, contributing to better breathing stability.

Flunisolide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Oral candidiasis: fungal infection of the mouth or throat. - Hoarseness: voice changes or hoarseness. - Throat irritation: soreness or irritation in the throat. - Cough: persistent cough after inhalation. - Dysphonia: difficulty speaking due to vocal cord irritation. - Dry mouth: reduced salivation leading to discomfort.

Serious or Rare Side Effects: - Adrenal suppression: reduced cortisol production. - Severe allergic reaction: anaphylaxis or angioedema. - Pneumonia: lower respiratory tract infection. - Immunosuppression: increased susceptibility to infections. - Oropharyngeal ulceration: painful lesions in the mouth. - Glaucoma or cataract formation: ocular pressure changes with long‑term use.

When using Nebulgen Adulti, consider the following precautions: - Monitor lung function: assess response and adjust therapy as needed. - Check for oral thrush: inspect mouth regularly and advise rinsing after use. - Evaluate adrenal function: consider in long‑term high‑dose therapy. - Use with caution in infections: respiratory infections may worsen. - Avoid abrupt discontinuation: taper to prevent adrenal crisis. - Store at room temperature: keep in original container, protect from moisture and heat.

Flunisolide may interact with other medicines; awareness of interaction severity helps guide safe use.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure. - Systemic corticosteroids: additive immunosuppressive effects. - Live vaccines: reduced efficacy and increased infection risk.

Moderate Interactions (Monitor Closely): - Beta‑agonists (e.g., albuterol): potential for reduced bronchodilator response. - Theophylline: may require serum level monitoring. - Antifungal azoles (e.g., fluconazole): may modestly increase flunisolide levels.